Actively Recruiting
Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics (PROSPECT): a National, Multicenter, Retrospective-prospective, Cohort Study
Led by First Affiliated Hospital Xi'an Jiaotong University · Updated on 2024-07-12
25000
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
Sponsors
F
First Affiliated Hospital Xi'an Jiaotong University
Lead Sponsor
X
Xi'an Gaoxin Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cardiovascular and cerebrovascular diseases, including coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke, remain major public health challenges with unclear causes and disease processes. This research aims to collect detailed clinical and biological data from patients with these conditions to better understand their underlying mechanisms. Using multi-omics technology, the study seeks to develop early prediction models and offer new approaches for personalized treatment of these diseases. Participants diagnosed with various cardiovascular or cerebrovascular diseases according to clinical guidelines, such as coronary artery disease, arrhythmia, heart valve disease, aortic dissection, cardiac masses, myocarditis, hypertension, cardiomyopathy, structural heart disease, ischemic or hemorrhagic cerebrovascular disease, and intracranial space occupying lesions, will be included. This observational study does not involve administering treatments but monitors patients over time to gather comprehensive data. During the study, participants will be regularly followed up with clinical visits and data collection, including biological specimens. Researchers will observe changes in major adverse cardiovascular and cerebrovascular events (MACCE) over up to five years, along with secondary outcomes like all-cause mortality, myocardial infarction, coronary revascularization, and stroke incidence. The study supports long-term monitoring to improve understanding and treatment strategies for these diseases.
CONDITIONS
Brief Title
Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who are regularly visited and followed up in the appropriate patient department.
- Patients diagnosed with at least one of the following cardiovascular or cerebrovascular diseases: coronary artery disease, arrhythmia, heart valve disease, aortic dissection, cardiac masses, myocarditis, hypertension, cardiomyopathy, structural heart disease, ischemic cerebrovascular disease, hemorrhagic cerebrovascular disease, or intracranial space occupying lesion.
You will not qualify if you...
- Age younger than 3 years or older than 80 years.
- Pregnant or lactating women.
- Patients who decline to provide informed consent.
- Patients unable to sign informed consent due to coma or other reasons without a legal representative to sign instead, especially if recovery of consciousness is unlikely.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who undergo routine care are observed to collect clinical data and biological specimens for up to 5 years to understand disease mechanisms and prognosis.
Regular visits during routine care
Trial Site Locations
Total: 1 location
1
First Affiliated Hospital of Xian Jiantong University
Xi'an, Shaanxi, China, 710061
Actively Recruiting
Research Team
G
Gouliang Li
Y
Yang Yan
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
12
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here